- Home
- OMCL vs IMCR Comparison
OMCL vs IMCR Comparison
Compare OMCL & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | IMCR |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OMCL | IMCR |
|---|---|---|
| Price | $50.77 | $33.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $49.83 | ★ $64.30 |
| AVG Volume (30 Days) | ★ 568.3K | 298.9K |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,177,740,000.00 | $379,590,000.00 |
| Revenue This Year | $8.61 | $32.28 |
| Revenue Next Year | $4.22 | $10.66 |
| P/E Ratio | $120.80 | ★ N/A |
| Revenue Growth | 10.67 | ★ 28.11 |
| 52 Week Low | $22.66 | $23.15 |
| 52 Week High | $55.00 | $40.72 |
Technical Indicators
Market Signals| Indicator | OMCL | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 72.70 | 41.29 |
| Support Level | $49.00 | $31.78 |
| Resistance Level | $51.84 | $35.78 |
| Average True Range (ATR) | 1.30 | 1.54 |
| MACD | 0.17 | -0.18 |
| Stochastic Oscillator | 82.43 | 25.75 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.